Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Carboplatin

8 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCPHI14126

09/03/2015

An OpenLabel Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX803 as a Single Agent and in Combination With Carboplatin in Subjects With Advanced Solid Tumors or Lymphoma.

Treatment

ECOGUROEA8141

08/27/2015

A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

Treatment

VICCTHO1443

03/11/2015

A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Treatment

ECOGHNE3311

08/29/2014

Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Treatment

VICCTHO1444

08/05/2014

A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate Efficacy and Safety of Roniciclib in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) Who are Receiving Cisplatin + Etoposide or Carboplatin + Etoposide as First-Line Therapy

Treatment

VICCPHI1360

04/22/2014

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

Treatment

VICCGI1211

03/08/2013

Phase IB/II Study of Induction Chemotherapy with XELOX, followed by Radiation Therapy, Carboplatin and RAD001 in Patients with Esophageal Cancer

Treatment

ECOGTHO4508-M

12/07/2010

Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy